Role of the Endocannabinoid System in Alcoholic Liver Disease

973 CANNABINOID RECEPTOR TYPE 1 EXPRESSION MODULATES ALCOHOL-INDUCED LIVER FIBROSIS: ROLE OF ACETALDEHYDE

(2010) E. Patsenker et al.   JOURNAL OF HEPATOLOGY

791 BENEFICIAL EFFECTS OF CANNABINOID RECEPTOR 2 ON ALCOHOLIC LIVER DISEASE

(2010) A. Louvet et al.   JOURNAL OF HEPATOLOGY

The Cannabinoid 1 Receptor (CNR1) 1359 G/A Polymorphism Modulates Susceptibility to Ulcerative Colitis and the Phenotype in Crohn's Disease

(2010) Martin Storr et al.   PLoS One

Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis

(2009) Martin A. Storr et al.   INFLAMMATORY BOWEL DISEASES

Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases

(2008) Pál Pacher et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Paracrine Activation of Hepatic CB1 Receptors by Stellate Cell-Derived Endocannabinoids Mediates Alcoholic Fatty Liver

(2008) Won-il Jeong et al.   Cell Metabolism

Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages

(2008) Koichi Sugamura et al.   CIRCULATION

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

(2008) Douglas Osei-Hyiaman et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors

(2008) Martin A. Storr et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Endocannabinoids and Liver Disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis

(2007) Sören V. Siegmund et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY